Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.73 |
| ▸ | PPARG | P37231 | 5/20 | 0.73 |
| ▸ | F7 | P08709 | 4/20 | 0.73 |
| ▸ | F3 | P13726 | 4/20 | 0.73 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.73 |
| ▸ | PPARD | Q03181 | 4/20 | 0.73 |
| ▸ | PPARA | Q07869 | 4/20 | 0.73 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.73 |
| ▸ | FABP3 | P05413 | 3/20 | 0.73 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.73 |
| ▸ | LMNA | P02545 | 2/20 | 0.73 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.73 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.73 |
| ▸ | FABP4 | P15090 | 2/20 | 0.73 |
| ▸ | HPGD | P15428 | 2/20 | 0.73 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.73 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.73 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.73 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.73 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18325614 | 1.00 | ALDH1A1 (0.73) | ALDH1A1PPARGF7F3KDM4E | |
| SCHEMBL15908483 | 1.00 | ALDH1A1 (0.73) | ALDH1A1PPARGF7F3KDM4E | |
| SCHEMBL2621471 | 1.00 | ALDH1A1 (0.73) | ALDH1A1PPARGF7F3KDM4E | |
| SCHEMBL15908489 | 1.00 | ALDH1A1 (0.73) | ALDH1A1PPARGF7F3KDM4E | |
| SCHEMBL15908476 | 1.00 | ALDH1A1 (0.73) | ALDH1A1PPARGF7F3KDM4E | |
| SCHEMBL11893268 | 1.00 | ALDH1A1 (0.73) | ALDH1A1PPARGF7F3KDM4E | |
| SCHEMBL9183242 | 1.00 | ALDH1A1 (0.73) | ALDH1A1PPARGF7F3KDM4E | |
| SCHEMBL3414485 | 1.00 | ALDH1A1 (0.73) | ALDH1A1PPARGF7F3KDM4E | |
| SCHEMBL21302754 | 1.00 | ALDH1A1 (0.73) | ALDH1A1PPARGF7F3KDM4E | |
| SCHEMBL10740192 | 0.98 | PPARG (0.72) | ALDH1A1PPARGF7F3KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230332071-A1 | MACROCYCLIC MUSK LACTONES AND USES THEREOF | PHYTO TECH CORP. | 2023-10-19 | — | — | US | disclosed |
| US-20230323244-A1 | MACROCYCLIC MUSK LACTONES AND USES THEREOF | PHYTO TECH CORP (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230265429-A1 | SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF | Arrowhead Pharmaceuticals, Inc. | 2023-08-24 | — | — | US | disclosed |
| US-20230226193-A1 | LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS | Arrowhead Pharmaceuticals, Inc. | 2023-07-20 | — | — | US | disclosed |
| US-11639483-B2 | Macrocyclic musk lactones and uses thereof | PHYTO TECH CORP. (US) | 2023-05-02 | — | — | US | disclosed |
| US-20210323992-A1 | GEMCITABINE PRODRUGS | CURE BIOPHARMA INC. | 2021-10-21 | — | — | US | disclosed |
| WO-2017208088-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON'S DISEASE | CELLIX BIO PRIVATE LIMITED (IN) | 2017-12-07 | — | — | WO | disclosed |
| US-9833002-B2 | Biocide compositions | ECOLAB USA INC. (US) | 2017-12-05 | — | — | US | disclosed |
| WO-2017037661-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON'S DISEASE | CELLIXBIO PRIVATE LIMITED (IN) | 2017-03-09 | — | — | WO | disclosed |
| US-20160374346-A1 | BIOCIDE COMPOSITIONS | NORRISEAL-WELLMARK, INC. | 2016-12-29 | — | — | US | disclosed |
| WO-2016203352-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | MOHAN M ALAPATI (IN) | 2016-12-22 | — | — | WO | disclosed |
| US-9374999-B2 | Biocide compositions | ECOLAB USA INC. (US) | 2016-06-28 | — | — | US | disclosed |
| US-9102791-B2 | Alkoxylated sorbitan esters as crude oil emulsion breakers | ECOLAB USA INC. (US) | 2015-08-11 | — | — | US | disclosed |
| US-20150038470-A1 | BIOCIDE COMPOSITIONS | NORRIS RODS, INC., | 2015-02-05 | — | — | US | disclosed |
| US-20140213668-A1 | ALKOXYLATED SORBITAN ESTERS AS CRUDE OIL EMULSION BREAKERS | ECOLAB USA INC. (US) | 2014-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11639483-B2 | Macrocyclic musk lactones and uses thereof | MGLL, UGCG, DAGLA | ALDH1A1 2005/4885PPARG 347/4885F7 2573/4885 |
| US-20230226193-A1 | LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS | CPT1B, MUSK, MYLK2 | ALDH1A1 1330/4885PPARG 271/4885F7 4629/4885 |
| US-20210323992-A1 | GEMCITABINE PRODRUGS | TYMP, PIK3CA, DCK | ALDH1A1 2877/4885PPARG 869/4885F7 4597/4885 |
| US-20140213668-A1 | ALKOXYLATED SORBITAN ESTERS AS CRUDE OIL EMULSION BREAKERS | SCD, SORBS1, ALK | ALDH1A1 2056/4885PPARG 165/4885F7 3958/4885 |
| US-20150038470-A1 | BIOCIDE COMPOSITIONS | ABHD6, MGLL, GUSB | ALDH1A1 1945/4885PPARG 1915/4885F7 3920/4885 |
| US-20230323244-A1 | MACROCYCLIC MUSK LACTONES AND USES THEREOF | MGLL, UGCG, DAGLA | ALDH1A1 2005/4885PPARG 347/4885F7 2573/4885 |
| US-20160374346-A1 | BIOCIDE COMPOSITIONS | ABHD6, MGLL, GUSB | ALDH1A1 1945/4885PPARG 1915/4885F7 3920/4885 |
| US-20230265429-A1 | SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF | MUSK, MYLK2, TNNC1 | ALDH1A1 2528/4885PPARG 498/4885F7 3177/4885 |
| US-20230332071-A1 | MACROCYCLIC MUSK LACTONES AND USES THEREOF | MGLL, UGCG, DAGLA | ALDH1A1 2005/4885PPARG 347/4885F7 2573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.